Friday 9th June 2023 |
Text too small? |
Infratil Limited (“Infratil“) (NZX/ASX: IFT) is pleased to advise that it has successfully completed the underwritten [1] placement (“Placement”) component of its planned NZ$850 million equity raising announced yesterday.
The Placement raised a total of $750 million at a price of NZ$9.20, representing a discount of 8.9% to the last close price on the NZX of NZ$10.10 on Tuesday, 6 June 2023 and a 7.9% discount to 5-day VWAP of NZ$9.99.
The Placement was strongly supported attracting bids well in excess of the offer amount from both existing and new investors in local and offshore markets, including broker firm clients. Eligible shareholders who bid for up to their pro-rata share of new shares under the Placement were allocated their full bid.
Infratil CEO, Jason Boyes, said, “We are very pleased with the strong level of support received for the Placement, particularly from our existing shareholders. The additional capital will be deployed towards our acquisition of a further stake in One NZ and provides flexibility to support our attractive pipeline of investment opportunities”.
Settlement of the Placement is expected to occur on Tuesday, 13 June 2023 on the ASX and Wednesday, 14 June 2023 on the NZX. Allotment of the new shares issued under the Placement is expected to occur on Wednesday, 14 June 2023 with trading of the new shares commencing on the NZX and ASX on the same date.
Retail Offer
The non-underwritten retail share offer (“Retail Offer“) announced on 7 June will open next Tuesday, 13 June 2023. A Retail Offer document will be made available to eligible shareholders on Tuesday, 13 June 2023, and can also be accessed on the website established for the Retail Offer https://www.infratilshareoffer.com/.
All eligible shareholders are encouraged to visit the website and apply online before the closing date at 5.00pm New Zealand time / 3.00pm Sydney time on Tuesday, 27 June 2023.
Further information
Further details of the equity raising and our acquisition of One NZ are set out in the Investor Presentation we released to the NZX and ASX yesterday.
Any enquiries should be directed to:
Mark Flesher, Investor Relations, Infratil Limited mark.flesher@infratil.com
Footnote
1. The Placement was fully underwritten, other than in respect of pre-committed pro rata participation in the Placement by interests associated with Morrison & Co and related parties amounting to $43.7 million worth of new shares in the aggregate.
NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES
The distribution of this announcement in jurisdictions outside New Zealand and Australia may be restricted by law and you should observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this announcement may not be distributed or released in the United States.
This announcement does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or in any jurisdiction in which such an offer would be illegal. The securities to be offered and sold in the Placement and the Retail Offer have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or the securities laws of any state or other jurisdiction of the United States. Accordingly, the securities to be offered and sold in the Placement may not be offered or sold, directly or indirectly, in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable securities laws of any state or other jurisdiction of the United States. The securities to be offered and sold in the Retail Offer may not be offered or sold, directly or indirectly, in the United States or to any person that is acting for the account or benefit of a person in the United States.
No comments yet
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors
December 19th Morning Report